MDGL MADRIGAL PHARMACEUTICALS INC US FDA Inspections 8-K Filing 2024 - FDA Approval of Rezdiffra for NASH Treatment Madrigal Pharmaceuticals announced that the FDA has granted accelerated approval of Rezdiffra for the treatment of noncirrhotic NASH with liver fibrosis.Get access to all SEC 8-K filings of the MADRIGAL PHARMACEUTICALS INC